BayMark Health Services, a portfolio company of Webster Capital, has acquired Canadian Addiction Treatment Centres (CATC). Financial terms were not disclosed.
Canadian Addiction Treatment Centres is the largest opioid addiction treatment provider in Canada. The acquisition includes 72 Opioid Treatment Programs (OTPs), 19 pharmacies and 1 residential treatment center located in Ontario.
Lewisville, Texas based BayMark Health Services provides medication-assisted treatment to more than 45,000 patients in recovery from opioid use disorder.
Webster Capital formed BayMark Health Services from BAART Programs (acquired in June 2015) and MedMark Services (acquired in October 2015).
CATC is BayMark’s first international acquisition and 8th since its formation.
photo credit: Canadian Addiction Treatment Centres (CATC)
BAYMARK HEALTH SERVICES ACQUIRES CANADIAN ADDICTION TREATMENT CENTRES
BayMark’s first international acquisition makes them the leading provider of opioid addiction treatment in North America.
LEWISVILLE, TX (March 2, 2018) – BayMark Health Services announced the acquisition of Canadian Addiction Treatment Centres (CATC), the largest opioid addiction treatment provider in Canada. The acquisition includes 72 Opioid Treatment Programs (OTPs), 19 pharmacies and 1 residential treatment center located in Ontario. This acquisition positions BayMark as the largest provider of opioid addiction treatment in North America with 167 locations across the U.S. and Canada.
“Canadian Addiction Treatment Centres and BayMark have grown similarly in their respective markets by providing evidence-based, individualized treatment to address the staggering need created by the opioid crisis,” shared David K. White, Ph.D., Chief Executive Officer of BayMark Health Services. “We have known of CATC and the leadership team for some time, and both organizations have been working to improve treatment access to combat this rapidly growing problem in the U.S. and Canada. The timing was right for us to bring the two companies together to share our knowledge and expertise in designing the optimal programs to treat individuals with Opioid Use Disorder.”
The opioid epidemic has been making headlines for some time now as more than 115 Americans die each day of an opioid overdose and millions of Americans struggle with opioid use. In Canada, while the overdose numbers aren’t quite as extreme, the problem has nonetheless reached epidemic proportions with approximately 600,000 Canadians misusing prescription medications costing the country more than $40 billion in economic burden.
Cam Crawford, the CEO of CATC noted, “We are very pleased to be joining the BayMark family of addiction treatment programs and look forward to the increased impact we may have in treating opiate addiction and the associated complications that arise from such addictions. BayMark shares our value system which focuses on comprehensive medical, pharmaceutical, and psycho-social care for those with opioid use disorder. Together we have an opportunity to make a difference in an epidemic that has hit both the U.S. and Canada in a profound way.”
CATC programs will retain its name and management team, providing continuity of care for the more than 14,000 patients currently receiving treatment.
Following the acquisition, BayMark will operate a total of 167 programs; 145 Opioid Treatment Programs, 8 office-based buprenorphine assisted treatment programs, 13 outpatient detoxification facilities and one residential treatment location across 26 states and 1 province in North America.
For more information on BayMark Health Services or Canadian Addiction Treatment Centres visit the websites at: BayMark.com & Canatc.ca.
About BayMark Health Services:
BayMark Health Services, headquartered in Lewisville, Texas, provides medication-assisted treatment to more than 45,000 patients in recovery from opioid use disorder. Our outpatient programs deliver medically supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of prescription pain medication or other opiates. The BayMark continuum of patient- focused services includes highly structured opioid treatment programs utilizing methadone or buprenorphine and office-based buprenorphine programs, both of which incorporate counseling as part of an individualized treatment plan; as well as, ambulatory withdrawal management services with naltrexone therapy, residential treatment and recovery support services.